Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT06397911
This study is recruiting at 6 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Atopic Dermatitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Oneness Biotech Co., Ltd.
- Last updated on ClinicalTrials.gov
- June 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 4
- First OC Dermatology · Fountain Valley, CA
- Center for Dermatology Clinical Research, Inc. · Fremont, CA
- California Allergy and Asthma Medical Group · Los Angeles, CA
- University of California, Davis Health, Department of Dermatology · Sacramento, CA
Texas · 2
- UT Health Science Houston · Bellaire, TX
- Center for Clinical Studies · Webster, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.